Research programme: antibodies - AnaptysBio/Gilead
Latest Information Update: 28 Apr 2022
At a glance
- Originator AnaptysBio; Gilead Sciences
- Developer AnaptysBio; Gilead Sciences; Ligand Pharmaceuticals
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 08 Jul 2016 Gilead Sciences in-licenses OmniRat®, OmniMouse® and OmniFlic® platforms from Ligand Pharmaceuticals to develop antibodies